Lifecore Biomedical (LFCR) Competitors

$4.36 -0.04 (-0.91%)

As of 12:26 PM Eastern

LFCR vs. CYRX, CTMX, STRO, CADL, and TLRY

Should you buy Lifecore Biomedical stock or one of its competitors? MarketBeat compares Lifecore Biomedical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lifecore Biomedical include CryoPort (CYRX), CytomX Therapeutics (CTMX), Sutro Biopharma (STRO), Candel Therapeutics (CADL), and Tilray Brands (TLRY). These companies are all part of the "pharmaceutical products" industry.

How does Lifecore Biomedical compare to CryoPort?

Lifecore Biomedical (NASDAQ:LFCR) and CryoPort (NASDAQ:CYRX) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

CryoPort has a net margin of 41.57% compared to Lifecore Biomedical's net margin of -25.43%. CryoPort's return on equity of -7.92% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-25.43%	-1,643.15%	-14.40%
CryoPort	41.57%	-7.92%	-4.79%

83.4% of Lifecore Biomedical shares are held by institutional investors. Comparatively, 92.9% of CryoPort shares are held by institutional investors. 32.7% of Lifecore Biomedical shares are held by company insiders. Comparatively, 10.1% of CryoPort shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Lifecore Biomedical currently has a consensus target price of $6.00, suggesting a potential upside of 37.61%. CryoPort has a consensus target price of $14.44, suggesting a potential upside of 9.33%. Given Lifecore Biomedical's higher possible upside, analysts plainly believe Lifecore Biomedical is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
CryoPort	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

In the previous week, CryoPort had 2 more articles in the media than Lifecore Biomedical. MarketBeat recorded 4 mentions for CryoPort and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.93 beat CryoPort's score of 0.71 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CryoPort	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CryoPort has higher revenue and earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.27	-$35.26M	-$0.94	N/A
CryoPort	$176.18M	3.78	$78.30M	$1.35	9.78

Lifecore Biomedical has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, CryoPort has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market.

Summary

CryoPort beats Lifecore Biomedical on 13 of the 16 factors compared between the two stocks.

How does Lifecore Biomedical compare to CytomX Therapeutics?

Lifecore Biomedical (NASDAQ:LFCR) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

CytomX Therapeutics has lower revenue, but higher earnings than Lifecore Biomedical. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.27	-$35.26M	-$0.94	N/A
CytomX Therapeutics	$76.20M	7.81	-$17.37M	-$0.41	N/A

Lifecore Biomedical has a net margin of -25.43% compared to CytomX Therapeutics' net margin of -166.40%. CytomX Therapeutics' return on equity of -36.61% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-25.43%	-1,643.15%	-14.40%
CytomX Therapeutics	-166.40%	-36.61%	-28.02%

83.4% of Lifecore Biomedical shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 32.7% of Lifecore Biomedical shares are held by company insiders. Comparatively, 6.6% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Lifecore Biomedical currently has a consensus target price of $6.00, suggesting a potential upside of 37.61%. CytomX Therapeutics has a consensus target price of $12.78, suggesting a potential upside of 265.60%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CytomX Therapeutics is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, CytomX Therapeutics had 12 more articles in the media than Lifecore Biomedical. MarketBeat recorded 14 mentions for CytomX Therapeutics and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.93 beat CytomX Therapeutics' score of 0.82 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Lifecore Biomedical has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market.

Summary

CytomX Therapeutics beats Lifecore Biomedical on 9 of the 16 factors compared between the two stocks.

How does Lifecore Biomedical compare to Sutro Biopharma?

Lifecore Biomedical (NASDAQ:LFCR) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Lifecore Biomedical has higher revenue and earnings than Sutro Biopharma. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.27	-$35.26M	-$0.94	N/A
Sutro Biopharma	$102.48M	5.77	-$191.09M	-$17.20	N/A

Lifecore Biomedical has a net margin of -25.43% compared to Sutro Biopharma's net margin of -154.21%. Sutro Biopharma's return on equity of 0.00% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-25.43%	-1,643.15%	-14.40%
Sutro Biopharma	-154.21%	N/A	-69.20%

83.4% of Lifecore Biomedical shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 32.7% of Lifecore Biomedical shares are held by company insiders. Comparatively, 5.9% of Sutro Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Lifecore Biomedical currently has a consensus target price of $6.00, suggesting a potential upside of 37.61%. Sutro Biopharma has a consensus target price of $43.78, suggesting a potential upside of 22.66%. Given Lifecore Biomedical's higher probable upside, equities research analysts plainly believe Lifecore Biomedical is more favorable than Sutro Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Sutro Biopharma	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85

In the previous week, Sutro Biopharma had 4 more articles in the media than Lifecore Biomedical. MarketBeat recorded 6 mentions for Sutro Biopharma and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.93 beat Sutro Biopharma's score of 0.05 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sutro Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lifecore Biomedical has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market.

Summary

Sutro Biopharma beats Lifecore Biomedical on 9 of the 17 factors compared between the two stocks.

How does Lifecore Biomedical compare to Candel Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

Candel Therapeutics has a beta of -0.59, meaning that its share price is 159% less volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

Candel Therapeutics has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -25.43%. Candel Therapeutics' return on equity of -60.42% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-60.42%	-41.33%
Lifecore Biomedical	-25.43%	-1,643.15%	-14.40%

Lifecore Biomedical has higher revenue and earnings than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A
Lifecore Biomedical	$128.87M	1.27	-$35.26M	-$0.94	N/A

In the previous week, Candel Therapeutics had 12 more articles in the media than Lifecore Biomedical. MarketBeat recorded 14 mentions for Candel Therapeutics and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.93 beat Candel Therapeutics' score of 0.06 indicating that Lifecore Biomedical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Lifecore Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Candel Therapeutics presently has a consensus target price of $18.00, suggesting a potential upside of 121.54%. Lifecore Biomedical has a consensus target price of $6.00, suggesting a potential upside of 37.61%. Given Candel Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Candel Therapeutics is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are owned by institutional investors. 14.3% of Candel Therapeutics shares are owned by insiders. Comparatively, 32.7% of Lifecore Biomedical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Lifecore Biomedical beats Candel Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Lifecore Biomedical compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

Tilray Brands has a beta of 1.94, meaning that its share price is 94% more volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

9.4% of Tilray Brands shares are owned by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are owned by institutional investors. 0.8% of Tilray Brands shares are owned by insiders. Comparatively, 32.7% of Lifecore Biomedical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Lifecore Biomedical has a net margin of -25.43% compared to Tilray Brands' net margin of -156.51%. Tilray Brands' return on equity of -3.31% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-156.51%	-3.31%	-2.42%
Lifecore Biomedical	-25.43%	-1,643.15%	-14.40%

Lifecore Biomedical has lower revenue, but higher earnings than Tilray Brands. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$821.31M	0.73	-$2.19B	-$13.65	N/A
Lifecore Biomedical	$128.87M	1.27	-$35.26M	-$0.94	N/A

In the previous week, Tilray Brands had 8 more articles in the media than Lifecore Biomedical. MarketBeat recorded 10 mentions for Tilray Brands and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.93 beat Tilray Brands' score of 0.45 indicating that Lifecore Biomedical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tilray Brands	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lifecore Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tilray Brands presently has a consensus target price of $11.50, suggesting a potential upside of 124.04%. Lifecore Biomedical has a consensus target price of $6.00, suggesting a potential upside of 37.61%. Given Tilray Brands' stronger consensus rating and higher probable upside, analysts plainly believe Tilray Brands is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Tilray Brands beats Lifecore Biomedical on 9 of the 16 factors compared between the two stocks.

Get Lifecore Biomedical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LFCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LFCR vs. The Competition

Export

Metric	Lifecore Biomedical	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$163.58M	$3.27B	$6.23B	$12.22B
Dividend Yield	N/A	2.34%	2.81%	5.30%
P/E Ratio	-4.64	18.47	20.55	25.17
Price / Sales	1.27	281.56	544.49	71.25
Price / Cash	N/A	55.27	27.48	37.27
Price / Book	10.38	6.60	9.71	6.65
Net Income	-$35.26M	$24.40M	$3.56B	$335.32M
7 Day Performance	-3.11%	-2.50%	-1.66%	-1.61%
1 Month Performance	-18.96%	-2.70%	-2.35%	-0.96%
1 Year Performance	-36.72%	58.02%	31.59%	28.59%

Lifecore Biomedical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LFCR Lifecore Biomedical	1.7978 of 5 stars	$4.36 -0.9%	$6.00 +37.6%	-36.1%	$163.58M	$128.87M	N/A	690
CYRX CryoPort	3.4053 of 5 stars	$13.04 -1.0%	$14.44 +10.7%	+96.7%	$663.80M	$176.18M	9.66	1,186
CTMX CytomX Therapeutics	3.1764 of 5 stars	$3.88 +0.5%	$12.78 +229.3%	+77.8%	$656.92M	$76.20M	N/A	170
STRO Sutro Biopharma	2.7182 of 5 stars	$40.91 +4.1%	$40.78 -0.3%	+327.5%	$651.28M	$102.48M	N/A	240	Earnings Report Analyst Forecast
CADL Candel Therapeutics	3.864 of 5 stars	$8.72 -1.5%	$18.00 +106.4%	+63.9%	$648.44M	N/A	N/A	60	Earnings Report Analyst Upgrade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LFCR) was last updated on 5/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lifecore Biomedical (LFCR) Competitors

LFCR vs. CYRX, CTMX, STRO, CADL, and TLRY

How does Lifecore Biomedical compare to CryoPort?

Summary

How does Lifecore Biomedical compare to CytomX Therapeutics?

Summary

How does Lifecore Biomedical compare to Sutro Biopharma?

Summary

How does Lifecore Biomedical compare to Candel Therapeutics?

Summary

How does Lifecore Biomedical compare to Tilray Brands?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFCR vs. The Competition

Lifecore Biomedical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lifecore Biomedical (LFCR) Competitors

LFCR vs. CYRX, CTMX, STRO, CADL, and TLRY

How does Lifecore Biomedical compare to CryoPort?

Is LFCR or CYRX more profitable?

Do insiders and institutionals have more ownership in LFCR or CYRX?

Do analysts prefer LFCR or CYRX?

Does the media prefer LFCR or CYRX?

Which has preferable valuation & earnings, LFCR or CYRX?

Which has more risk & volatility, LFCR or CYRX?

Summary

How does Lifecore Biomedical compare to CytomX Therapeutics?

Which has better valuation and earnings, LFCR or CTMX?

Is LFCR or CTMX more profitable?

Do institutionals and insiders have more ownership in LFCR or CTMX?

Do analysts rate LFCR or CTMX?

Does the media prefer LFCR or CTMX?

Which has more volatility and risk, LFCR or CTMX?

Summary

How does Lifecore Biomedical compare to Sutro Biopharma?

Which has better valuation and earnings, LFCR or STRO?

Is LFCR or STRO more profitable?

Do institutionals and insiders have more ownership in LFCR or STRO?

Do analysts rate LFCR or STRO?

Does the media prefer LFCR or STRO?

Which has more volatility and risk, LFCR or STRO?

Summary

How does Lifecore Biomedical compare to Candel Therapeutics?

Which has more volatility and risk, CADL or LFCR?

Is CADL or LFCR more profitable?

Which has stronger earnings & valuation, CADL or LFCR?

Does the media favor CADL or LFCR?

Do analysts recommend CADL or LFCR?

Do insiders & institutionals hold more shares of CADL or LFCR?

Summary

How does Lifecore Biomedical compare to Tilray Brands?

Which has more volatility and risk, TLRY or LFCR?

Do insiders & institutionals hold more shares of TLRY or LFCR?

Is TLRY or LFCR more profitable?

Which has stronger earnings & valuation, TLRY or LFCR?

Does the media favor TLRY or LFCR?

Do analysts recommend TLRY or LFCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFCR vs. The Competition

Lifecore Biomedical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools